Laboratory Corporation of America Holdings
NYSE:LH

Watchlist Manager
Laboratory Corporation of America Holdings Logo
Laboratory Corporation of America Holdings
NYSE:LH
Watchlist
Price: 253.89 USD -0.22% Market Closed
Market Cap: 21B USD

Intrinsic Value

The intrinsic value of one LH stock under the Base Case scenario is 292.75 USD. Compared to the current market price of 253.89 USD, Laboratory Corporation of America Holdings is Undervalued by 13%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

LH Intrinsic Value
292.75 USD
Undervaluation 13%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Laboratory Corporation of America Holdings

What is Valuation History?
Ask AI Assistant
What other research platforms think about LH?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is LH valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Laboratory Corporation of America Holdings.

Explain Valuation
Compare LH to

Fundamental Analysis

Company Overview
Loading...
Business Segments
Loading...
Economic Moat
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
Bear Theses

Increasing competition from both major players like Quest Diagnostics and emerging at-home testing startups could erode LabCorp’s market share and compress margins, given the company’s reliance on high-volume contracts for profitability.

Regulatory and reimbursement uncertainties, especially around Medicare and private insurer cost-cutting efforts, may lead to downward pricing pressure on diagnostic tests, constraining LabCorp’s ability to maintain robust revenue growth.

Slow integration or underperformance of acquired research assets, particularly from its Covance acquisition, could weigh on the company’s resources and distract from core diagnostic services, limiting cross-selling opportunities.

Bull Theses

LabCorp’s unique combination of leading diagnostic laboratory services and contract research operations positions it to capture growth from the rising demand for both advanced genetic testing and pharmaceutical clinical trials globally.

Strategic partnerships with hospitals, health systems, and pharmaceutical companies provide LabCorp with valuable access to volume-based testing contracts and early-stage clinical trial work, helping sustain higher utilization of its diagnostic platforms.

Ongoing investments in digital capabilities and patient-centric innovations, such as remote sample collection and expanded online service portals, could enhance LabCorp’s brand appeal and improve patient retention, driving incremental revenue gains.

Show More Less
How do you feel about LH?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Laboratory Corporation of America Holdings

Current Assets 4.1B
Cash & Short-Term Investments 598.1m
Receivables 2.3B
Other Current Assets 1.2B
Non-Current Assets 14.2B
Long-Term Investments 168.2m
PP&E 3.1B
Intangibles 10.3B
Other Non-Current Assets 648.1m
Current Liabilities 2.6B
Accounts Payable 668.5m
Accrued Liabilities 1.1B
Other Current Liabilities 896m
Non-Current Liabilities 6.9B
Long-Term Debt 5.1B
Other Non-Current Liabilities 1.8B
Efficiency

Free Cash Flow Analysis
Laboratory Corporation of America Holdings

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Laboratory Corporation of America Holdings

Revenue
13.8B USD
Cost of Revenue
-9.8B USD
Gross Profit
3.9B USD
Operating Expenses
-2.6B USD
Operating Income
1.4B USD
Other Expenses
-509.7m USD
Net Income
855.2m USD
Fundamental Scores

LH Profitability Score
Profitability Due Diligence

Laboratory Corporation of America Holdings's profitability score is 47/100. The higher the profitability score, the more profitable the company is.

Healthy Gross Margin
Sustainable 3Y Average Gross Margin
Sustainable 3Y Average Operating Margin
Positive ROE
47/100
Profitability
Score

Laboratory Corporation of America Holdings's profitability score is 47/100. The higher the profitability score, the more profitable the company is.

LH Solvency Score
Solvency Due Diligence

Laboratory Corporation of America Holdings's solvency score is 48/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Low D/E
Long-Term Solvency
Short-Term Solvency
48/100
Solvency
Score

Laboratory Corporation of America Holdings's solvency score is 48/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

LH Price Targets Summary
Laboratory Corporation of America Holdings

Wall Street analysts forecast LH stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for LH is 305.75 USD with a low forecast of 262.6 USD and a high forecast of 359.1 USD.

Lowest
Price Target
262.6 USD
3% Upside
Average
Price Target
305.75 USD
20% Upside
Highest
Price Target
359.1 USD
41% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for LH is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

LH News

Other Videos
What is the Intrinsic Value of one LH stock?

The intrinsic value of one LH stock under the Base Case scenario is 292.75 USD.

Is LH stock undervalued or overvalued?

Compared to the current market price of 253.89 USD, Laboratory Corporation of America Holdings is Undervalued by 13%.

Back to Top